Epstein‐Barr virus LMP2A utilizes Syk and PI3K to activate NF‐κB in B‐cell lymphomas to increase MIP‐1α production

Abstract

The incidence of Hodgkin's lymphoma (HL) is growing due to an increase in Epstein‐Barr virus (EBV)‐associated HL in AIDS patients. The HL tumor microenvironment is vital for the survival of the malignant Hodgkin‐Reed Sternberg (HRS) cells of HL, which express the EBV protein latent membrane protein 2A (LMP2A). While previous work shows that LMP2A mimics B‐cell receptor (BCR) signaling to promote the survival of HRS cells, the ability of LMP2A to establish and maintain the tumor microenvironment through the production of chemokines remains unknown. Since BCR signaling induces the production of the chemokine macrophage inflammatory protein‐1α (MIP‐1α), and since LMP2A is a BCR mimic, we hypothesized that LMP2A increases MIP‐1α levels. A comparison of multiple LMP2A‐negative and ‐positive cell lines demonstrates that LMP2A increases MIP‐1α. Additionally, LMP2A‐mutant cell lines and pharmacologic inhibitors indicate that LMP2A activates a Syk/PI3K/NF‐κB pathway to enhance MIP‐1α. Finally, based on the finding that an NF‐κB inhibitor decreased MIP‐1α RNA/protein in LMP2A‐positive cells, we are the first to demonstrate that LMP2A increases the nuclear localization of the NF‐κB p65 subunit using DNA‐binding assays and confocal microscopy in human B cells. These findings not only have implications for the treatment of HL, but also other LMP2A‐expressing B‐cell tumors that overexpress NF‐κB.

RETRACTED: Integrated bioinformatic analysis of key biomarkers and signalling pathways in psoriasis

“…Luster et al previously highlighted the relationship between chemokines and inflammation, likely explaining their predicted role in psoriasis patients. 40 IRF7, IFIT3, OAS1, GBP1, and ISG15 were also identified as promising targets for the treatment of psoriasis. Raposo et al detected significant upregulation of 16 different antiviral genes in lesional psoriatic skin, with ISG15 expression being increased more than two-fold, 41 and others have similarly observed cutaneous upregulation of antiviral proteins in the context of psoriasis, 42 potentially explaining why these patients rarely experience cutaneous viral infections.…”

Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma

“…The 4 class I PI3K isozymes (PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ) regulate a variety of cellular functions, and the δ isoform is specifically involved in B-cell signaling and regulates B-cell response to chemokines and cytokines [122,123]. In vitro exposure of HRS cells to a specific inhibitor of PI3Kδ resulted in increased levels of apoptosis [124]. Based on these findings, Idelalisib, a selective inhibitor of PI3Kδ, was administered to patients affected by relapsed/refractory cHL in a phase II study [107]: compared to other B-cell malignancies, the activity of Idelalisib in this patient population was modest, with only a 20% response rate.…”

The effectiveness of tamsulosin hydrochloride with terazosin combination therapy for chronic prostatitis Type-III b

“… 14 Previous studies have shown that patients with chronic prostatitis have higher concentrations of MIP-2 and MIP-1α in their prostatic fluid, and that the levels of these cytokines are positively correlated with the severity of chronic prostatitis. 15 This study noted that combination therapy with tamsulosin hydrochloride and terazosin decreased IL-2, PGE-2, MIP-1α, and MIP-2 levels. This indicates that this therapeutic approach inhibited patient inflammatory responses.…”